Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

This article is part of the supplement: Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access Oral presentation

Incidence of Kaposi Sarcoma in HIV-infected patients – a prospective multi-cohort study from Southern Africa

Julia Bohlius1*, Fabio Valeri1, Mhairi Maskew2, Hans Prozesky3, Cleophas Chimbetete4, Priscilla Lumano-Mulenga5, Daniela Garone6, Thomas Gsponer1 and Matthias Egger1

Author Affiliations

1 Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland

2 Health Economics and Epidemiology Research Office, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa

3 Division of Infectious Diseases, Department of Medicine, University of Stellenbosch, Cape Town, South Africa

4 Newlands Clinic, Harare, Zimbabwe

5 Centre for Infectious Diseases and Research in Zambia, Lusaka, Zambia

6 Medecins Sans Frontieres, South Africa

For all author emails, please log on.

Infectious Agents and Cancer 2012, 7(Suppl 1):O20  doi:10.1186/1750-9378-7-S1-O20

The electronic version of this article is the complete one and can be found online at: http://www.infectagentscancer.com/content/7/S1/O20


Published:19 April 2012

© 2012 Bohlius et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

The incidence of Kaposi Sarcoma (KS) is high in sub-Saharan Africa. Data on KS among HIV-infected patients receiving and not yet receiving antiretroviral therapy (ART) are, however, scarce in Africa. Within the framework of a large multi-cohort project, the International epidemiologic Database to Evaluate AIDS (IeDEA), we estimate the incidence and risk factors for the development of KS in HIV-infected patients in Southern Africa.

Methods

We analyzed prospectively collected data of HIV-infected children and adults participating in IeDEA-SA. We included all patients who were ART naive at start of observation, regardless of cancer history, with at least 30 days follow up. Prevalent KS cases were also excluded. Incidence rates and 95% confidence intervals (CI) were calculated based on the Poisson distribution; risk factors were estimated using crude and adjusted Cox proportional hazard models. Hazard ratios (HR) with 95% CI and medians with interquartile ranges (IQR) are presented.

Results

We included 184,592 patients from 10 cohort studies in Botswana, Mozambique, South Africa, Zambia and Zimbabwe. The median age was 34 years (IQR 28–41), the median CD4 cell count at first contact was 152 cells/µl (IQR 75-252) and 146 cells/µl (IQR 74-226) at start of ART. 61% of patients were female. During a total follow-time of 391,852 person-years, 349 patients developed KS before starting ART, 585 developed KS after starting ART and 183,658 remained KS-free. In patients not receiving ART the KS incidence rate was 624 (95% CI 562–692) per 100,000 person-years and in patients receiving ART the KS incidence rate was 174 (95% CI 161-189) per 100,000 person-years, rate ratio for ART versus no ART = 0.28 (95% CI 0.24 - 0.32). Univariate and multivariate analyses showed that men were more likely than women to develop KS and that the incidence rate for KS increased with increasing age and with decreasing CD4 cell counts. These effects were more pronounced in patients not receiving ART than in patients receiving ART.

Conclusions

In Southern African countries with a high prevalence of HHV-8 the risk of developing KS in HIV infected patients receiving ART increases steeply with age and immune-suppression. ART reduced the incidence of KS substantially.

Acknowledgement

This work was done on behalf of The International epidemiologic Database to Evaluate AIDS (IeDEA) Study Group. This study was funded by grants from NIAID, NICHD, NCI (number U01AI069924), PEPFAR (number 3U01AI069924-05S2) and the Swiss Bridge Foundation.